Halofantrine, (-)- | CAS#66051-76-1 | antimalarial drug

MedKoo Cat#: 598147 | Name: Halofantrine, (-)-

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Halofantrine, (-)- is an antimalarial drug.

Chemical Structure

Halofantrine, (-)-

CAS#66051-76-1

Theoretical Analysis

MedKoo Cat#: 598147

Name: Halofantrine, (-)-

CAS#: 66051-76-1

Chemical Formula: C26H30Cl2F3NO

Exact Mass: 499.1657

Molecular Weight: 500.42

Elemental Analysis: C, 62.40; H, 6.04; Cl, 14.17; F, 11.39; N, 2.80; O, 3.20

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Halofantrine, (-)-; L-WR-171669;

IUPAC/Chemical Name

3-(dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol

InChi Key

FOHHNHSLJDZUGQ-UHFFFAOYSA-N

InChi Code

InChI=1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3

SMILES Code

OC(CCN(CCCC)CCCC)C1=CC2=C(Cl)C=C(Cl)C=C2C3=CC(C(F)(F)F)=CC=C31

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 500.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Wesche DL, Schuster BG, Wang WX, Woosley RL. Mechanism of cardiotoxicity of halofantrine. Clin Pharmacol Ther. 2000 May;67(5):521-9. Review. PubMed PMID: 10824631. 2: Peters W, Robinson BL, Ellis DS. The chemotherapy of rodent malaria. XLII. Halofantrine and halofantrine resistance. Ann Trop Med Parasitol. 1987 Oct;81(5):639-46. PubMed PMID: 3331253. 3: ter Kuile FO, Dolan G, Nosten F, Edstein MD, Luxemburger C, Phaipun L, Chongsuphajaisiddhi T, Webster HK, White NJ. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet. 1993 Apr 24;341(8852):1044-9. PubMed PMID: 8096956. 4: Singh N, Puri SK. Modulation of halofantrine resistance after coadministration of halofantrine with diverse pharmacological agents in a rodent malaria model. Life Sci. 2000 Aug 4;67(11):1345-54. PubMed PMID: 10972203. 5: Karbwang J, Na Bangchang K. Clinical pharmacokinetics of halofantrine. Clin Pharmacokinet. 1994 Aug;27(2):104-19. Review. PubMed PMID: 7955774. 6: Kolade YT, Babalola CP, Olaniyi AA, Scriba GK. Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. Eur J Clin Pharmacol. 2008 Jan;64(1):77-81. Epub 2007 Oct 20. PubMed PMID: 17952423. 7: Krishna S, ter Kuile F, Supanaranond W, Pukrittayakamee S, Teja-Isavadharm P, Kyle D, White NJ. Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. Br J Clin Pharmacol. 1993 Dec;36(6):585-91. PubMed PMID: 12959277; PubMed Central PMCID: PMC1364665. 8: Bassi PU, Onyeji CO, Ukponmwan OE. Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. Br J Clin Pharmacol. 2004 Jul;58(1):52-5. PubMed PMID: 15206992; PubMed Central PMCID: PMC1884545. 9: Brocks DR, Toni JW. Pharmacokinetics of halofantrine in the rat: stereoselectivity and interspecies comparisons. Biopharm Drug Dispos. 1999 Apr;20(3):165-9. PubMed PMID: 10211870. 10: Mosqueira VC, Loiseau PM, Bories C, Legrand P, Devissaguet JP, Barratt G. Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice. Antimicrob Agents Chemother. 2004 Apr;48(4):1222-8. PubMed PMID: 15047523; PubMed Central PMCID: PMC375247. 11: Karbwang J, Milton KA, Na Bangchang K, Ward SA, Edwards G, Bunnag D. Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria. Br J Clin Pharmacol. 1991 Apr;31(4):484-7. PubMed PMID: 2049260; PubMed Central PMCID: PMC1368339. 12: Baune B, Flinois JP, Furlan V, Gimenez F, Taburet AM, Becquemont L, Farinotti R. Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. J Pharm Pharmacol. 1999 Apr;51(4):419-26. PubMed PMID: 10385214. 13: Simooya OO, Sijumbil G, Lennard MS, Tucker GT. Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol. 1998 Mar;45(3):315-7. PubMed PMID: 10896408; PubMed Central PMCID: PMC1873379. 14: Mbai M, Rajamani S, January CT. The anti-malarial drug halofantrine and its metabolite N-desbutylhalofantrine block HERG potassium channels. Cardiovasc Res. 2002 Sep;55(4):799-805. PubMed PMID: 12176129. 15: Anabwani G, Canfield CJ, Hutchinson DB. Combination atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in children. Pediatr Infect Dis J. 1999 May;18(5):456-61. PubMed PMID: 10353520. 16: Batey AJ, Coker SJ. Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes. Br J Pharmacol. 2002 Feb;135(4):1003-12. PubMed PMID: 11861329; PubMed Central PMCID: PMC1573214. 17: Veenendaal JR, Parkinson AD, Kere N, Rieckmann KH, Edstein MD. Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine. Eur J Clin Pharmacol. 1991;41(2):161-4. PubMed PMID: 1743249. 18: Batey AJ, Lightbown ID, Lambert JP, Edwards G, Coker SJ. Comparison of the acute cardiotoxicity of the antimalarial drug halofantrine in vitro and in vivo in anaesthetized guinea-pigs. Br J Pharmacol. 1997 Oct;122(3):563-9. PubMed PMID: 9351516; PubMed Central PMCID: PMC1564961. 19: Halliday RC, Jones BC, Smith DA, Kitteringham NR, Park BK. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. Br J Clin Pharmacol. 1995 Oct;40(4):369-78. PubMed PMID: 8554939; PubMed Central PMCID: PMC1365156. 20: Gimenez F, Gillotin C, Basco LK, Bouchaud O, Aubry AF, Wainer IW, Le Bras J, Farinotti R. Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients. Eur J Clin Pharmacol. 1994;46(6):561-2. PubMed PMID: 7995326.